esophageal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 at the time of signing the informed consent; 2. Patients with late locally advanced esophageal cancer confirmed by histopathological examination; 3. Have not received immune checkpoint therapy drugs (PD-1/PD-L1/CTLA4, etc.), and have not previously undergone surgery, chemotherapy, radiotherapy or targeted therapy; 4. At least one measurable tumor lesion was present according to RECISTv1.1 criteria; 5. No central nervous system metastasis occurred; 6. The ECOG PS score is 0 or 1; 7. Patients or family members are willing to cooperate with complete medication tracking requirements
Exclusion criteria
Exclusion criteria: 1. The patient has metastases of brain and other nervous system; 2. Acute or chronic hepatitis B or C infection; 3. Active, known or suspected autoimmune diseases (except type I diabetes, hypothyroidism requiring hormone replacement therapy, skin diseases, etc., without systemic treatment); 4. Prior malignancies (other than carcinoma in situ such as lung, bladder, stomach, colon, endometrial, breast, etc.), unless they had been in complete remission at least 2 years prior to study participation and no additional treatment was required during the study period; 5. Received any chemotherapy, biologics for cancer, or experimental therapies within 28 days prior to initial dosing; 6. Patients who refused or could not complete the communication related to informed consent of the study, or patients who withdrew from the study for some reason during the study; 7. Consult the researcher for other exclusions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive predictive value;Negative predictive value; | — |
Countries
China
Contacts
Cancer Hospital, Chinese Academy of Medical Sciences